How Neura Is Reinventing Brain Health With Personalized Nutrigenomics

The Supplement Aisle Is Lying to You

Walk into any pharmacy or health food store and you'll find an entire wall dedicated to brain health. Lion's mane. Alpha-GPC. Phosphatidylserine. Omega-3s. The labels all promise sharper focus, faster recall, better mood. And they're all selling you the exact same thing — a one-size-fits-all formula designed for a statistically average human who doesn't actually exist.

Here's the problem: your brain is not average. The way your neurons fire, the way your body synthesizes and breaks down neurotransmitters, the way you respond to B-vitamins, the way you manage neuroinflammation — all of it is encoded in your genome. A supplement that dramatically improves focus for someone with a specific COMT variant may do nothing — or actively backfire — for someone without it. The science has known this for years. The supplement industry just hasn't caught up.

Neura is catching up.

What Neura Actually Does

Neura's model is elegantly simple in concept and genuinely sophisticated in execution. It starts with a saliva test — mailed to your door, completed in two minutes, returned in a prepaid envelope. From that sample, Neura's lab analyzes over 80 genetic variants relevant to cognitive function and brain health. These aren't vanity markers. They're clinically meaningful polymorphisms with direct implications for how you should supplement:

• COMT and MAO variants — govern how fast your brain breaks down dopamine and norepinephrine. Fast metabolizers and slow metabolizers need fundamentally different approaches to cognitive support.
• MTHFR polymorphisms — affect methylation pathways and B-vitamin utilization. Someone with the C677T variant cannot efficiently convert folic acid to its active form; they need methylfolate directly.
• APOE status — one of the strongest known genetic predictors of neuroinflammation risk and long-term cognitive resilience.
• BDNF variants — influence neuroplasticity, the brain's ability to form new connections in response to learning and experience.

From this genomic profile, Neura formulates a custom supplement stack manufactured in an FDA-registered facility. This isn't a generic capsule with your name on the label. The ingredient selection, the dosing, and even the molecular form of each nutrient — methylfolate versus folic acid, methylcobalamin versus cyanocobalamin — are all determined by your specific genetic architecture.

But Neura doesn't stop at delivery. Every subscriber receives access to a cognitive tracking protocol — a structured battery of tests measuring working memory, processing speed, and mood — completed periodically via the Neura app. This closes the loop: your genomic profile informs your formula, your formula influences your cognition, and your cognitive data feeds back into refining your stack. It's a living, iterating system, not a static product.

Who Neura Is Built For

Neura occupies a specific and underserved intersection of the health market. Its ideal customer isn't someone casually browsing the supplement aisle — it's someone who has already decided that their cognitive performance matters and is frustrated that nothing on the market treats them as an individual.

Think of the high-performing professional in their 40s who's tried a dozen nootropic stacks and can never tell what's working. The graduate student or researcher who wants to optimize learning capacity but is wary of stimulants. The 55-year-old who watched a parent decline cognitively and wants to take proactive, evidence-based steps now. The biohacker who's already done 23andMe but doesn't know how to translate their raw genetic data into actionable supplementation.

These are people who value precision. They read ingredient labels. They understand the difference between clinical dosing and label-dressing. They've been waiting for a supplement company that takes the science as seriously as they do.

Why Neura Stands Apart

The personalized supplement space has attracted some notable players — Care/of, Persona, Ritual — but none of them start with your DNA. They start with a lifestyle questionnaire and return a curated selection from a catalog of off-the-shelf products. That's personalized marketing, not personalized medicine.

Neura's differentiation is rooted in actual biological individuality:

The cognitive tracking layer is especially important strategically. Most supplement companies have no way to prove their products work — and customers have no way to know either. Neura's built-in measurement protocol creates a feedback loop that generates real, individual-level data. Over time, this data becomes a moat: Neura will have the world's largest dataset correlating specific genomic profiles with cognitive supplement responses. That's a research asset with implications far beyond the supplement market.

"We're not selling brain pills. We're building a precision brain health platform." — Neura founding vision

The Market Opportunity

The convergence of several powerful trends makes this the right moment for Neura. The global nootropics and cognitive supplement market is valued at over $8 billion and growing steadily, driven by an aging population increasingly focused on cognitive longevity and a younger cohort of knowledge workers treating mental performance as a competitive advantage.

Meanwhile, direct-to-consumer genetic testing has gone mainstream. Over 30 million people have taken consumer DNA tests. The infrastructure — labs, logistics, regulatory familiarity — that once made genetic testing exotic is now commoditized. What hasn't been built yet is the actionable layer on top of that data for brain health specifically.

Personalized nutrition broadly is on a steep growth curve, projected to expand at a 17.6% compound annual growth rate through the decade. Within that, the precision supplementation segment — where actual biochemical individuality drives formulation — is nascent but accelerating. Neura is positioned at the leading edge of that curve, in the highest-value subcategory: the brain.

Regulatory tailwinds matter too. The FDA's increasing scrutiny of unsubstantiated supplement claims is actually a competitive advantage for evidence-based players like Neura. As the bar for credibility rises, companies with genuine science backing and personalized protocols will pull further ahead of commoditized competitors.

Built With AI, Backed by Science

Neura was conceived, structured, and launched using Artha — an AI platform that compresses the typically multi-year process of building a company into a matter of days. From brand identity to product logic to go-to-market positioning, Artha helped translate the scientific foundation of nutrigenomics into a fully operational business architecture.

The result is a company that moves with startup speed but carries the intellectual rigor of an academic research program. Neura's advisory board includes neurogenomics researchers from UCSF and formulators with decades of experience in evidence-based supplementation. The science is real. The personalization is real. And the platform behind it was built to scale.

This is what AI-native company building looks like: not replacing expertise, but accelerating its translation into market-ready products. Artha handled the scaffolding; the science team handled the substance.

What's Next for Neura

The supplement stack is the beachhead, not the destination. Neura's roadmap points toward a full precision brain health platform — one where genetic profiling anchors an expanding suite of interventions including sleep protocols, nutrition guidance, and eventually pharmaceutical-adjacent nutraceuticals as regulatory pathways evolve.

The cognitive tracking data collected from subscribers will compound in value as the user base grows. Patterns between specific genetic profiles and measurable cognitive outcomes, at scale, represent a dataset that doesn't yet exist anywhere. That asset positions Neura for partnerships with academic institutions, longevity clinics, and eventually health systems looking to operationalize preventive cognitive care.

There's also a compelling international expansion story. MTHFR prevalence, APOE distribution, and COMT variant frequencies vary significantly across ethnic populations — meaning Neura's personalization logic becomes more powerful, not less, as it serves more diverse genomic populations.

The near-term focus is on proving the model: building a subscriber base of precision-minded customers, validating cognitive outcomes through the tracking protocol, and using those results to anchor clinical credibility. The story Neura will be able to tell in 24 months — with real genomic-to-outcome data behind it — is the story that changes the supplement industry.

Build Your Own Precision Health Company on Artha

Neura is one example of what becomes possible when deep domain expertise meets AI-powered company building. The idea had been sitting in the space between neuroscience and nutrition for years — it just needed the right infrastructure to move from insight to launch.

If you have a market insight, a problem worth solving, or an industry you know is ready to be disrupted, Artha can help you build the company around it — faster than you think, and more completely than you'd expect. From brand to product to go-to-market, in a single prompt.

Your company is one idea away. Start building on Artha →